|
Daily Medical Update
Ulcerative colitis
Tuesday, September 08, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Digestive diseases and sciences (2026) - Systematic Review and Meta-analysis of Randomized Controlled Trials
Key Findings
- Clinical response improved versus placebo during induction (RR 2.47) and maintenance (RR 3.30).
- Clinical remission, endoscopic improvement, histological remission, and mucosal healing all improved in both induction and maintenance phases; adverse events were slightly increased, but serious adverse events and discontinuations did not differ significantly from placebo.
📋 Practice Implication: S1P modulators are a credible oral option for moderate-to-severe UC when both symptom control and tissue-level healing are treatment goals, with monitoring for non-serious adverse effects.
|
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026) - Systematic Review and Meta-Analysis
Key Findings
- Short-term clinical response was 77.9% with tofacitinib and 86.5% with upadacitinib; short-term colectomy rates were 11.5% and 11.2%, respectively.
- Reported adverse events included venous thromboembolism in 2.2%, major adverse cardiovascular events in 0.7%, and herpes zoster in 3.4%; tofacitinib and upadacitinib had similar overall outcomes.
📋 Practice Implication: JAK inhibitors can serve as rapid rescue or adjunctive therapy with intravenous corticosteroids in acute severe UC, but inpatient decisions should include thrombosis, cardiovascular, and herpes-zoster risk assessment.
|
International journal of colorectal disease (2025) - Systematic Review and Meta-analysis of Randomized Controlled Trials
Key Findings
- IL-23 inhibitors increased clinical remission during induction (RR 1.52) and maintenance (RR 1.62) compared with placebo.
- Histo-endoscopic healing improved during induction (RR 2.53) and maintenance (RR 1.81), while serious adverse events were reduced during induction (RR 0.39).
📋 Practice Implication: IL-23 blockade offers a sustained remission and mucosal-healing strategy for moderate-to-severe UC, especially when a favorable induction safety profile is a priority.
|
Journal of Crohn's & colitis (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 17,441 pregnancies, pooled rates were 8.2% for early pregnancy loss, 8.9% for preterm birth, 0.3% for stillbirth, 6.6% for low birth weight, and 2.9% for congenital malformations.
- Active disease, older maternal age, and longer disease duration were associated with selected complications; third-trimester exposure did not increase complication risk enough to support routine treatment discontinuation.
📋 Practice Implication: For pregnant patients with UC, prioritize sustained remission and individualized maternal-fetal monitoring rather than routinely stopping advanced therapy solely because of third-trimester exposure.
|
PloS one (2025) - Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Key Findings
- Among 19 studies involving 5,450 patients, Qing-Chang-Hua-Shi ranked highest for induction remission (SUCRA 0.89), cyclosporine for treatment response (SUCRA 0.90), and tacrolimus for mucosal healing (SUCRA 0.89); these outcomes were not uniformly improved by one therapy.
- Recombinant interferon-β-1a had the lowest serious-adverse-event risk ranking, and no single therapy consistently improved remission, response, mucosal healing, and safety outcomes together.
📋 Practice Implication: After conventional-therapy failure, choose second-line treatment according to the immediate clinical target and patient risk profile instead of applying a single universal drug hierarchy.
|
|
💡
Summary
The selected evidence supports several effective advanced-therapy strategies for moderate-to-severe ulcerative colitis, including S1P modulators, IL-23 inhibitors, and JAK inhibitors for acute severe disease. Treatment selection remains context dependent: refractory disease benefits from outcome-specific ranking, while pregnancy data support maintaining remission with individualized monitoring rather than routine discontinuation of therapy.
|
|